Event

To Ignore or Not to Ignore? Transfusing Patients with Multiple Alloantibodies (21EL-612)

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Wednesday, March 10, 2021 - On-Demand Available
Program Number: 21EL-612

  • Educational Track: Technical/Clinical
  • Topics: Antibody Identification, Complications, Immunohematology, Patient Transfusion, Transfusion Process
  • Intended Audience: Directors, Hospital Blood Banks, Hospitals, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
  • Teaching Level: Basic, Intermediate
  • Director/Moderator: Lisa M. Shave MS, MLS(ASCP)CMSBBCM, Medical Laboratory Technology Program Coordinator & Professor, MLT Coordinator at Mercer County Community College, West Windsor, NJ, Blood Bank Medical Laboratory Scientist, MLS at Pennsylvania Hospital, Philadelphia, PA
    Speakers:

    • Jeanne Hendrickson, MD, Professor of Laboratory Medicine; Medical Director of Apheresis Service/Laboratory Medicine; Associate Director, Transfusion Medicine Service, Yale University/Yale New Haven Hospital, New Haven, CT
    • Rebecca Ross, MA Ed, BS, MT (ASCP), SBB, Manager, Yale New Haven Blood Banks, Yale New Haven Hospital, New Haven, CT
    • Sean Stowell, MD, Associate Professor, Department of Pathology, Harvard University, Brigham and Women’s Hospital, Boston, MA
  • Program Description

    Red cell alloimmunization may occur during or after blood transfusions, evoking the immune system to produce alloantibodies. This program focuses on the induced response and reviews clinically significant versus clinically insignificant alloantibodies in patients who receive multiple transfusions with an emphasis on case examples.

    Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Describe clinically significant antibodies.
    • Define antibodies that are clinically insignificant.
    • Discuss strategies to work through which antibodies may be transfused against in emergency situations.

    Registration

    Please note: if you registered for the live eCast you do not need to register for this on-demand eCast (access to the on-demand eCast was included with the live eCast registration).

    Single Viewer Register
    Group Viewing Register

    Continuing Education Credit

    AABB designates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

    Speaker Biographies

    Jeanne Hendrickson, MD is a pediatric hematologist and transfusion medicine specialist. Her clinical interests include factors influencing alloimmunization (particularly red blood cell alloimmunization), as well as strategies to minimize the formation and dangers of such antibodies. Her research interests include investigating the induction and consequences of red blood cell alloantibodies in transfusion and pregnancy situations, in murine models and in the clinical setting.

    Rebecca Ross, MA Ed, BS, MT (ASCP), SBB is the manager of the Yale New Haven Hospital Blood Banks. She has worked in laboratory medicine for many years, including the past 20 at Yale. In addition to having oversight of the blood banks, she teaches MLS students, clinical pathology residents, transfusion medicine fellows, hematology/oncology fellows, and others.

    Sean Stowell, MD is a clinical pathologist and immunologist, with interests in RBC alloantibodies, inhibitors to factor VIII, neonatal transfusion medicine, and glycobiology, among others. His translational research laboratory evaluates factors influencing RBC alloantibodies as well as the consequences of these antibodies.